| Outcome Measures: |
Primary: Change from baseline in HbA1c after 26 weeks of treatment, Calculated based on HbA1c level measured in plasma, Baseline, Week 26 | Secondary: Proportion of subjects that achieved HbA1c<7% after 12, 26 weeks of treatment, Calculated based on HbA1c level measured in plasma, Week 12, Week 26|Proportion of subjects that achieved HbA 1c ≤ 6.5% after 12, 26 weeks of treatment, Calculated based on HbA1c level measured in plasma, Week 12, Week 26|Changes from baseline in fasting plasma glucose (FPG) after 12, 26 weeks of treatment, Calculated based on FPG level measured in plasma, Baseline, Week 12, Week 26|Change from baseline in 7-point SMBG values after 12, 26 weeks of treatment, Calculated based on 7-point SMBG values, Baseline, Week 12, Week 26|Change from baseline in body weight after 12, 26 weeks of treatment, Calculated based on body weight measurement, Baseline, Week 12, Week 26|Number of treatment emergent adverse events, Count, From Baseline to Week 27|Number of treatment emergent hypoglycaemic episodes, Count, From Baseline to Week 27|Number of participants with injection site reactions, Count (spontaneous pain, tenderness, itching, redness, edema, induration/infiltration), From Baseline to Week 27|Incidence of anti-drug antibodies (ADA), and neutralising antibodies (if applicable), Calculated based on the values of anti-drug antibodies (ADA), and neutralising antibodies (if applicable), Baseline, Week 12, 26, and 27 (if applicable)|Plasma concentrations of degludec, liraglutide, Calculated based on plasma concentrations of degludec, liraglutide, Baseline, Week 2, 6, 12, 20, 26
|
